Know Cancer

forgot password

The Borealis-2 Clinical Trial: A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination With OGX-427 in Patients With Relapsed or Refractory Metastatic Urothelial Carcinoma After Receiving a Platinum-containing Regimen: Hoosier Oncology Group GU12-160

Phase 2
18 Years
Open (Enrolling)
Bladder Cancer, Urothelial Carcinoma

Thank you

Trial Information

The Borealis-2 Clinical Trial: A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination With OGX-427 in Patients With Relapsed or Refractory Metastatic Urothelial Carcinoma After Receiving a Platinum-containing Regimen: Hoosier Oncology Group GU12-160

OUTLINE: This is a multi-center study.

Eligible patients will be stratified based on time from prior systemic chemotherapy (< 3 vs
≥ 3 months) and Bellmunt prognostic factors criteria, which include Eastern Cooperative
Oncology Group (ECOG) performance status >0, hemoglobin <10g/dL, and presence of liver
metastases (0 versus 1-3 risk factors). Within the strata, participants will be randomly
assigned with equal probability to either the investigational arm (Arm A: docetaxel +
OGX-427) or the control arm (Arm B: docetaxel alone).



Participants randomized onto the investigational arm (Arm A) will receive OGX-427 beginning
with a loading dose period prior to the initiation of docetaxel treatment. The first dose of
OGX-427 for the loading dose period must be administered within 5 working days of
registration and randomization.

During the loading dose period, participants will receive three separate administrations of
600 mg OGX-427 intravenously (IV) (days -9 to -1). There must be at least one "non-infusion"
day between each administration of OGX-427 (i.e., every other day) during the loading dose
period and between the third loading dose of OGX-427 and day 1 of cycle 1. There should be
no more than 7 days between the last loading dose and day 1 of cycle 1.


During the treatment period, participants randomized to this arm will receive:

- OGX-427 600 mg IV weekly on days 1, 8, and 15 of each 21-day cycle. OGX-427 must be
administered prior to docetaxel on day 1 of each cycle.

- Docetaxel (75 mg/M2) IV on day 1 of each 21-day cycle. Docetaxel should be administered
immediately following the completion of the OGX-427 infusion.


Following completion of 10 cycles of docetaxel, 600 mg OGX-427 will continue to be
administered by IV weekly as maintenance therapy for participants who do not have disease
progression (i.e., stable disease or better). Participants without documented disease
progression who have discontinued from study treatment not due to toxicity related to
OGX-427 can also continue to receive OGX-427 maintenance as long as they have completed
disease assessments following at least 2 cycles of chemotherapy. Maintenance with OGX-427
will continue until disease progression or unacceptable toxicity.



During the treatment period, participants randomized to this arm will receive:

- Docetaxel (75 mg/M2) IV on day 1 of each 21-day cycle. The first dose of docetaxel must be
administered within 5 working days of registration and randomization. Participants will
continue to receive docetaxel on day 1 of each 21-day cycle until disease progression,
unacceptable toxicity related to docetaxel, voluntary patient withdrawal, or a maximum of 10
docetaxel cycles.


Imaging studies will be performed every 6 weeks (i.e., after completion of cycles 2, 4, 6, 8
and 10) until disease progression and with any sign or symptom of new or worsening disease;
computed tomography scan (CT) of chest/abdomen/pelvis is preferred but magnetic resonance
imaging scan(MRI) is acceptable, especially for participants with increased risk of
contrast-related nephropathy or other contraindications. For Arm A, scans will be performed
every 2 cycles (6 weeks) +/1 week during the 21-day cycles of docetaxel administration and
every 6 weeks during maintenance OGX-427 administration until disease progression; for Arm
B, scans will be performed every 6 weeks during the 21-day cycles of docetaxel
administration until disease progression. All scans should be completed before the
subsequent cycle is scheduled to begin. Bone scans will be repeated, if positive at
baseline, every 6 weeks during the first 4 cycles of treatment (i.e., at the end of cycles 2
and 4) and then every 12 weeks thereafter until disease progression (i.e., at the end of
cycle 8, at end of treatment, and during maintenance with OGX-427 [Arm A only]).

All participants will have an End of Treatment (EOT) visit when they discontinue study
treatment. All participants will be followed until documented disease progression.

Once disease progression is documented, participants will enter a survival follow-up period.
All participants must be followed for survival as the primary endpoint. During the survival
follow-up period, data will be collected every three months regarding further cancer
therapy, secondary malignancy, and survival status.

Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Life Expectancy: Greater than 3 months


- Absolute neutrophil count(ANC)≥ 1,500/mcL

- Hemoglobin ≥ 8 g/dL

- Platelets ≥ 100,000/mcL


- Bilirubin ≤ 1.1 x upper limit of normal (ULN) (≤ 2.0 x ULN if secondary to Gilbert's

- Aspartate transaminase (AST), serum glutamic oxaloacetic transaminase (SGOT)/alanine
transaminase (ALT), serum glutamic pyruvic transaminase (SGPT) ≤ 1.5 X institutional


- Serum creatinine ≤ 1.5 x ULN


- Symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or
myocardial infarction within 3 months of randomization.

Inclusion Criteria:

- Participants must have histologically documented metastatic or locally inoperable
advanced urothelial carcinoma (bladder, urethra, ureter and renal pelvis) (T4b, N2,
N3, or M1 disease. NOTE: Aberrant differentiation such as squamous, glandular
(adenocarcinoma), and micropapillary are eligible unless the tumor is considered a
pure histological variant according to the pathology report. Participants with small
cell histology are not eligible.

- Participants must have measurable disease defined as at least one target lesion that
has not been irradiated and can be accurately measured in at least one dimension by
RECIST v1.1 criteria.

- Participants must have received prior systemic chemotherapy treatment for metastatic
urothelial carcinoma. NOTE: Up to 2 prior systemic chemotherapeutic regimens given
in the metastatic disease setting for urothelial carcinoma are allowed.

- Specifically, subjects must meet one or more of the following criteria:

1. Progression during or after treatment with a regimen that includes a platinum
salt (e.g., carboplatin or cisplatin) OR

2. Disease recurrence within one year after neoadjuvant or adjuvant platinum-based
systemic chemotherapy, measured from the date of last dose of chemotherapy or
surgery until the day the informed consent is signed

- Participants must be ≥18 years since no dosing or adverse event data are currently
available on the use of OGX-427 in participants <18 years of age.

- Minimum of 21 days have elapsed since prior major surgery or radiation therapy, with
recovery from any adverse events.

- The effects of OGX-427 on the developing human fetus are unknown. For this reason,
women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry and
for the duration of study participation. Should a woman become pregnant or suspect
she is pregnant while participating in this study, she should inform her treating
physician immediately.

- Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:

- History of treatment with docetaxel in any setting. Participants treated with prior
paclitaxel are eligible.

- Prior enrollment in the OncoGenex Phase 2 Study OGX-427-02.

- Participants may not be receiving other investigational agents.

- Participants with known brain or spinal cord metastases are excluded from this
clinical trial because of their poor prognosis and because they often develop
progressive neurologic dysfunction that would confound the evaluation of neurologic
and other adverse events. NOTE: Brain imaging is not required unless the patient has
symptoms or physical signs of central nervous system (CNS) disease.

- History of allergic reactions or severe hypersensitivity reactions to drugs
formulated with polysorbate 80 or antisense oligonucleotides.

- Peripheral neuropathy ≥Grade 2.

- Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection or psychiatric illness/social situations that would limit compliance with
study requirements.

- Cerebrovascular accident or pulmonary embolus within 3 months of randomization.

- Pregnant women and breast feeding women are excluded from this study because of the
risk to a fetus due to docetaxel chemotherapy and OGX-427 systemic treatment
(fertility toxicology studies have not been completed for OGX-427).

- Active second malignancy (except non-melanomatous skin cancer or incidental prostate
cancer found on cystectomy): active secondary malignancy is defined as a current need
for cancer therapy or a high possibility (>30%) of recurrence during the study.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression-Free Survival

Outcome Description:

To determine whether docetaxel administered in combination with OGX-427 provides a survival benefit compared to docetaxel alone.

Outcome Time Frame:

8 months

Safety Issue:


Principal Investigator

Noah Hahn, M.D.

Investigator Role:

Study Chair

Investigator Affiliation:

Hoosier Oncology Group


United States: Food and Drug Administration

Study ID:




Start Date:

April 2013

Completion Date:

April 2015

Related Keywords:

  • Bladder Cancer
  • Urothelial Carcinoma
  • OGX-427
  • Docetaxel
  • Urinary Bladder Neoplasms
  • Carcinoma
  • Carcinoma, Transitional Cell



Memorial Sloan-Kettering Cancer Center New York, New York  10021
Dana-Farber Cancer Institute Boston, Massachusetts  02115
City of Hope Duarte, California  91010
Methodist Cancer Center Omaha, Nebraska  68114
IU Health at Ball Memorial Hospital Muncie, Indiana  47303
Indiana University Melvin & Bren Simon Cancer Center Indianapolis, Indiana  46202
IU Health Central Indiana Cancer Centers Indianapolis, Indiana  46219